Latest news with #CeriBell
Yahoo
20-05-2025
- Business
- Yahoo
Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference
SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) ('Ceribell'), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45th Annual Growth Stock Conference. The presentation will take place on Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time. Event: William Blair 45th Annual Growth Stock ConferenceDate: Tuesday, June 3, 2025Time: 7:20 a.m. PST / 9:20 a.m. CST A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at About CeriBell, Inc. Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography ('EEG') platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence ('AI')-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for detecting suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit or follow the company on LinkedIn. Investor ContactBrian Johnston or Laine MorganGilmartin GroupInvestors@ Media ContactCorrie RosePress@
Yahoo
11-05-2025
- Business
- Yahoo
US$30.75: That's What Analysts Think CeriBell, Inc. (NASDAQ:CBLL) Is Worth After Its Latest Results
A week ago, CeriBell, Inc. (NASDAQ:CBLL) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. Results overall were credible, with revenues arriving 6.2% better than analyst forecasts at US$20m. Higher revenues also resulted in lower statutory losses, which were US$0.36 per share, some 6.2% smaller than the analysts expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on CeriBell after the latest results. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Taking into account the latest results, the most recent consensus for CeriBell from five analysts is for revenues of US$85.5m in 2025. If met, it would imply a solid 20% increase on its revenue over the past 12 months. Losses are forecast to balloon 26% to US$1.56 per share. Before this latest report, the consensus had been expecting revenues of US$83.7m and US$1.69 per share in losses. So there seems to have been a moderate uplift in analyst sentiment with the latest consensus release, given the upgrades to both revenue and loss per share forecasts for this year. View our latest analysis for CeriBell Yet despite these upgrades, the analysts cut their price target 7.5% to US$30.75, implicitly signalling that the ongoing losses are likely to weigh negatively on CeriBell's valuation. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic CeriBell analyst has a price target of US$36.00 per share, while the most pessimistic values it at US$26.00. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable. One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that CeriBell's revenue growth is expected to slow, with the forecast 27% annualised growth rate until the end of 2025 being well below the historical 44% growth over the last year. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 8.2% annually. So it's pretty clear that, while CeriBell's revenue growth is expected to slow, it's still expected to grow faster than the industry itself. The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business. With that in mind, we wouldn't be too quick to come to a conclusion on CeriBell. Long-term earnings power is much more important than next year's profits. We have forecasts for CeriBell going out to 2027, and you can see them free on our platform here. That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with CeriBell (at least 1 which is significant) , and understanding these should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
